膦甲酸钠联合阿德福韦酯治疗慢性乙型重型病毒性肝炎62例  

Foscarnet sodium and adefovir dipivoxil for treatment of 62 patients with chronic severe hepatitis B

作　　者：孙希平[1] 

机构地区：[1]山东省潍坊市益都中心医院感染科,262500

出　　处：《中国临床实用医学》2009年第1期24-25,共2页China Clinical Practical Medicine

摘　　要：目的探讨膦甲酸钠联合阿德福韦酯治疗慢性重型乙型肝炎的疗效。方法将123例慢性乙型重型肝炎患者随机分为对照组61例，给予治疗常规治疗加拉米夫定100mg，1次／d；治疗组62例，在常规治疗基础上加用膦甲酸钠和阿德福韦酯，膦甲酸钠注射液3．0g250ml，静脉滴注，2次／d，阿德福韦酯胶囊10mg，1次／d，疗程28d。结果肝功能复常率、HBV-DNA的阴转率治疗组优于对照组（P〈0．001）。治疗组肝性脑病、感染、肝肾综合征发生率分别为20．9％（13／62）、19．4％（12／62）、17．7％（11／62）明显低于对照组41．0％（25／61）、39．3％（24／61）、37．7％（23／61）差异有统计学意义（P〈0．05）。病死率：治疗组22．6％（14／62），显著低于对照组54．1％（33／61）（P〈0．01）。结论在基础保肝支持治疗同时，及时应用膦甲酸钠联合阿德福韦酯胶囊能显著提高慢性乙型重型肝炎的抢救成功率。Objective To investigate the effectiveness of foscarnet sodiumin and adefovir dipivoxil the treatment of patients with chronic severe hepatitis B. Methods 123 patients were randomly put in to a conventional Supporting treatment control group and a foscarnet sodium and adefovir treatment group. In the latter, 62 patients Were given foscarnet sodium and adefovir injection besides the support care which was also given to the control group. Results The rate of death in the foscarnct sodium and adefovir treatment group was significantly lower than control Group （ 22. 6 % vs 54. 1%, P 〈 0. 01 ）. There was significant difference between two group in there covery of liver function and HBVDNA negative rate. Inaddition, the rate of hepatic coma（ 20. 9% vs41.0% P 〈 0. 05 ）, infection （ 19.4% vs39.3 % P 〈 0. 05 ）, and hepatic kidney failure （ 17.7 % vs37.7% P 〈 0.05 ） in The foscamet sodium and adefovir treatment group were significant lower than control group. Conclusion Our results suggest that foscarnet sodium and adefovir administration with conventional supporting treatment has a good effectin patients with chronic severe hepatitis B.

关 键 词：慢性乙型重型肝炎 膦甲酸钠 阿德福韦酯胶囊 联合治疗 

分 类 号：R51[医药卫生—内科学]